Le Lézard
Classified in: Health
Subject: SVY

The global opioids market was valued at $18,532.8 million in 2018, and is expected to reach $22,387.2 million by 2026, registering a CAGR of 3.2% from 2019 to 2026


NEW YORK, Dec. 11, 2019 /PRNewswire/ --

Opioids Market by Product (Codeine, Fentanyl, Methadone, Oxycodone, Morphine, Hydrocodone and Others) and Application (Pain Management, Cough Treatment, and Diarrhea): Global Opportunity Analysis and Industry Forecast, 2019-2026

Read the full report: https://www.reportlinker.com/p05828848/?utm_source=PRN

The global opioids market was valued at $18,532.8 million in 2018, and is expected to reach $22,387.2 million by 2026, registering a CAGR of 3.2% from 2019 to 2026. Opioids are drugs that stimulate the brain to produce a variety of effects, including pain relief. The term opioid refers to all substances (exogenous or endogenous) that possess morphine-like properties. Opioids are the most widely prescribed medications to treat moderate to severe chronic pain. These analgesics are used to manage pain in cancer patients and to treat severe constant pain in patients who suffer from terminal illnesses.

The growth of the global opioids market is driven by alarming increase in incidence of orthopedic diseases & chronic pain. Furthermore, rise in disposable income and surge in global geriatric population are expected to propel the growth of the global opioids market. However, emergence and legalization of cannabis as an alternative to opioids impede the growth of the market. On the contrary, increase in consumption of opioid analgesic for pain management in developing countries is anticipated to create lucrative opportunities for market expansion in the near future.

The global opioid market is segmented into product, application, and region. Depending on product, the market is categorized into codeine, fentanyl, methadone, oxycodone, morphine, and hydrocodone. The applications covered in the market include pain management, cough treatment, and diarrhea treatment. The pain management segment is further classified into neuropathic pain, migraine, back pain, osteoarthritis pain, cancer pain, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Product Type
? Codeine
? Fentanyl
? Methadone
? Oxycodone
? Morphine
? Hydrocodone

By Application
? Pain Management
? Cough Treatment
? Diarrhea Treatment

By Region
? North America
o U.S.
o Canada
o Mexico
? Europe
o UK
o Germany
o France
o Spain
o Russia
o Rest of Europe
? Asia-Pacific
o China
o Japan
o India
o Australis
o South Korea
o Taiwan
o Rest of Asia-Pacific
? LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
? Purdue Pharma
? Boehringer Ingelheim
? Janssen Pharmaceuticals, Inc.
? Sanofi
? Sun Pharmaceuticals
? Mallinckrodt Pharmaceuticals
? Endo Pharmaceuticals Inc.
? Allergan, Plc
? Pfizer, Inc.

Read the full report: https://www.reportlinker.com/p05828848/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 20:35
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...

at 18:01
Aflac Incorporated announced today that it has revised the time of its first quarter webcast teleconference call on Thursday, May 2, 2024 to 7:00 a.m. (ET), which is one hour earlier than the originally scheduled 8:00 a.m. start time, to avoid...



News published on and distributed by: